• About Us
    • Contact Us
    • Login
    • ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
About Us Contact Us Login ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
Grand Rounds

Does Warfarin Protect Against Cancer?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Warfarin is the most commonly prescribed anticoagulant, used by 5 to 10% of adults in Western countries
  • Warfarin depletes vitamin K pools
  • Most vitamin K–dependent proteins are related to clotting but there is one protein, GAS6 (growth arrest–specific 6), that is associated with immune regulatory mechanisms related to cancer
  • There are conflicting previous epidemiological studies as to whether warfarin inhibits tumor growth, and decreases cancer incidence
  • Haaland et al. (JAMA Internal Medicine, 2017) evaluated the association between warfarin use and cancer incidence in a large, unselected population-based cohort

METHODS:

  • Population-based nationwide cohort study
  • Study cohort: All persons born between 1924 and 1954, living in Norway between 2006 and 2012
  • The cohort was divided into the following groups for analysis
    • Warfarin users
    • Nonusers
  • Warfarin users were further subdivided into those taking the medication for atrial fibrillation or atrial flutter
  • Primary outcome: Cancer diagnosis of any type during the 7-year observation period

RESULTS:

  • 1,256,725 individuals were included in the study
  • Warfarin users were older, with a mean (SD) age of 70.2 (8.2) years
    • Women comprised 52.7% of the nonusers and 38.3% of warfarin users
  • Warfarin users had significantly lower age- and sex-adjusted incidence rate ratio (IRR) for cancer
    • All cancer sites (IRR, 0.84; 95% CI, 0.82-0.86)
    • Prevalent organ-specific sites
      • Lung, 0.80 (95% CI, 0.75-0.86)
      • Prostate, 0.69 (95% CI, 0.65-0.72)
      • breast, 0.90 (95% CI, 0.82-1.00)
  • There was no observed significant effect in colon cancer
  • In a subgroup analysis of patients with atrial fibrillation or atrial flutter,  cancer IRR was lower for
    • All cancer sites (IRR, 0.62; 95% CI, 0.59-0.65)
    • Prevalent organ-specific sites
      • Lung, 0.39 (95% CI, 0.33-0.46)
      • Prostate, 0.60 (95% CI, 0.55-0.66)
      • Breast, 0.72 (95% CI, 0.59-0.87)
      • Colon, 0.71 [95% CI, 0.63-0.81)

CONCLUSION:

  • Warfarin appears to have broad anticancer potential
  • Especially in patients with arrhythmia, this study demonstrated “a remarkable association between warfarin use and lower cancer incidence”
  • While recognizing the benefits of the new anticoagulant agents, the authors suggest that an unintended consequence of switching away from warfarin may be increase cancer incidence

Learn More – Primary Sources:

Association of Warfarin Use With Lower Overall Cancer Incidence Among Patients Older Than 50 Years

image_pdfFavoriteLoadingFavorite

< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

Abnormal Vaginal Bleeding and Oral Anticoagulants for DVT – Results from the AMPLIFY trial
Can Genotype-Guided Dosing Decrease Warfarin Complications?

Sections

  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • COVID-19

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site